Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
BioCryst Pharmaceuticals Inc. has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. All these active matters are concentrated within 1 distinct art unit, which suggests a very specific technical focus for the company's current research and development. Despite this concentration in a single art unit, the workload is distributed among 3 distinct examiners, providing a variety of perspectives on the company's filings.
SAEED, KAMAL A is identified as the busiest examiner for the portfolio, currently handling 1 pending office action. This matter is among the active cases for the company. Because there are multiple examiners for the pending office actions, each matter is being reviewed by a different person within the same art unit. This creates a unique environment where the active cases are subject to the same art unit standards but different individual examiner interpretations. The strategy requires consistent messaging across all these pending office actions to ensure success in this technical field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAEED, KAMAL A | 1 | 83.9% | +9.8% |
| CORNET, JEAN P | 1 | 42.1% | +47.5% |
| HERNANDEZ, JACKSON J | 1 | 51.4% | +45.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18894797 | HUMAN PLASMA KALLIKREIN INHIBITORS | SAEED, KAMAL A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268688 | DOSING REGIMENS FOR ORAL ALK2 KINASE INHIBITORS | HERNANDEZ, JACKSON J | 56d |
| 18647310 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | CORNET, JEAN P | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18894797 | HUMAN PLASMA KALLIKREIN INHIBITORS | SAEED, KAMAL A | — | DP | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18647310 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | CORNET, JEAN P | — | §103§112DP | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18268688 | DOSING REGIMENS FOR ORAL ALK2 KINASE INHIBITORS | HERNANDEZ, JACKSON J | 1627 | §103Other | Final Rejection | 56d | Pending | Jun 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial